MXPA05005414A - Propargyl-trifluoromethoxy-amino-benzothiazole derivatives. - Google Patents
Propargyl-trifluoromethoxy-amino-benzothiazole derivatives.Info
- Publication number
- MXPA05005414A MXPA05005414A MXPA05005414A MXPA05005414A MXPA05005414A MX PA05005414 A MXPA05005414 A MX PA05005414A MX PA05005414 A MXPA05005414 A MX PA05005414A MX PA05005414 A MXPA05005414 A MX PA05005414A MX PA05005414 A MXPA05005414 A MX PA05005414A
- Authority
- MX
- Mexico
- Prior art keywords
- present
- integer
- alkyl
- propargyl
- trifluoromethoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The subject invention provides compounds having the structure (I): wherein R1 is present or absent, and when present is H, C1-C6alkyl, C1-C6 alkynyl, - (CH2)yS (CH2 )xCH3, C1-C6 aminoalkyl, C1-C6 hydroxyalkyl or -(CH2)nC(=0) (C6H4) (CH2)R2; R2 is H or C1-C4 alkyl; R3 is H or C1-C4 alkyl; R4 is present or absent, and when present is H, C1-C6 alkyl, C1-C6 alkynyl, - (CH2) yS (CH2)xCH3 , C1-C6 aminoalkyl, C1-C6 hydroxyalkyl or -(CH2) nC (=O) (C6H4) (CH2) R2; wherein n is an integer from 1-6; wherein x is 0 or an integer from 1-5 and y is an integer from 1-5, such that x+y<6; at least one of R1 or R4 is present; the dashed line represents a bond between one of the nitrogen atoms and the intervening carbon atom; and any compound is charged when both R1and R4 are present, or any specific enantiomer thereof or any pharmaceutically acceptable salt thereof, and a method for treating a neurologic disorder or multiple sclerosis by administering a therapeutically effective amount any of the compounds..
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30154002A | 2002-11-21 | 2002-11-21 | |
| PCT/US2003/037592 WO2004047756A2 (en) | 2002-11-21 | 2003-11-20 | Propargyl-trifluoromethoxy-amino-benzothiazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05005414A true MXPA05005414A (en) | 2006-05-25 |
Family
ID=32392394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05005414A MXPA05005414A (en) | 2002-11-21 | 2003-11-20 | Propargyl-trifluoromethoxy-amino-benzothiazole derivatives. |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1569641A2 (en) |
| JP (1) | JP2006507350A (en) |
| KR (1) | KR20050083951A (en) |
| CN (1) | CN1741802A (en) |
| AU (1) | AU2003295898A1 (en) |
| BR (1) | BR0315704A (en) |
| CA (1) | CA2507414A1 (en) |
| IS (1) | IS7906A (en) |
| MX (1) | MXPA05005414A (en) |
| NO (1) | NO20052979L (en) |
| RU (1) | RU2005119307A (en) |
| WO (1) | WO2004047756A2 (en) |
| ZA (1) | ZA200504988B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8759382B2 (en) | 2010-09-29 | 2014-06-24 | Teva Pharmaceutical Industries Ltd. | Propargyl-trifluoromethoxy-aminobenzothiazole derivatives, their preparation and use |
| CN103340859A (en) * | 2013-06-04 | 2013-10-09 | 中国科学院昆明动物研究所 | Method for establishing non-human primate animal model of parkinson disease by lateral ventricle administration of MPP<+> |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59112978A (en) * | 1982-12-21 | 1984-06-29 | Shionogi & Co Ltd | Propynylaminothiazole derivative |
-
2003
- 2003-11-20 EP EP03787112A patent/EP1569641A2/en not_active Withdrawn
- 2003-11-20 BR BR0315704-0A patent/BR0315704A/en not_active Application Discontinuation
- 2003-11-20 JP JP2004555702A patent/JP2006507350A/en active Pending
- 2003-11-20 WO PCT/US2003/037592 patent/WO2004047756A2/en not_active Application Discontinuation
- 2003-11-20 AU AU2003295898A patent/AU2003295898A1/en not_active Abandoned
- 2003-11-20 RU RU2005119307/04A patent/RU2005119307A/en not_active Application Discontinuation
- 2003-11-20 CN CNA2003801090823A patent/CN1741802A/en active Pending
- 2003-11-20 MX MXPA05005414A patent/MXPA05005414A/en not_active Application Discontinuation
- 2003-11-20 KR KR1020057009216A patent/KR20050083951A/en not_active Application Discontinuation
- 2003-11-20 ZA ZA200504988A patent/ZA200504988B/en unknown
- 2003-11-20 CA CA002507414A patent/CA2507414A1/en not_active Abandoned
-
2005
- 2005-06-17 NO NO20052979A patent/NO20052979L/en not_active Application Discontinuation
- 2005-06-22 IS IS7906A patent/IS7906A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2507414A1 (en) | 2004-06-10 |
| WO2004047756A3 (en) | 2004-07-08 |
| NO20052979L (en) | 2005-08-19 |
| JP2006507350A (en) | 2006-03-02 |
| IS7906A (en) | 2005-06-22 |
| ZA200504988B (en) | 2006-08-30 |
| WO2004047756A2 (en) | 2004-06-10 |
| EP1569641A2 (en) | 2005-09-07 |
| RU2005119307A (en) | 2006-01-27 |
| CN1741802A (en) | 2006-03-01 |
| AU2003295898A1 (en) | 2004-06-18 |
| KR20050083951A (en) | 2005-08-26 |
| BR0315704A (en) | 2005-09-06 |
| NO20052979D0 (en) | 2005-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW369526B (en) | Diazabicyclic neurokinin antagonists | |
| TWI266761B (en) | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents | |
| MY140525A (en) | Pharmaceutical uses for alpha2delta ligands | |
| MXPA04000411A (en) | Aryl substituted thiazolidinones and the use thereof. | |
| MXPA03001518A (en) | Composition and method for inhibiting platelet aggregation. | |
| GR3034520T3 (en) | 1-amidinophenyl-pyrrolidones piperidinones azetinones as platelet aggregation inhibitors | |
| MY111178A (en) | Antitumor compositions and methods of treatment | |
| AU4696897A (en) | Neurotrophin antagonist compositions | |
| PL308666A1 (en) | Derivatives of 11,21-bisphenyl-19-norpregnan, method of obtaining them and pharmaceutical composition containing such derivatives | |
| CA2064853A1 (en) | Indole derivatives | |
| NZ331801A (en) | Therapeutic agent for diabetes | |
| IL108695A (en) | Pharmaceutical composition comprising polyamine derivatives and some such novel compounds | |
| PT1044186E (en) | SUBSTITUTED 2-BENZYLAMINO-2-PHENYL-ACETAMIDE COMPOUND | |
| SG146681A1 (en) | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) | |
| MXPA05005414A (en) | Propargyl-trifluoromethoxy-amino-benzothiazole derivatives. | |
| TW333532B (en) | Benzopyrans | |
| HUP0402341A2 (en) | Compositions containing thiazol-2-ylamines for the treatment of cancer | |
| MY144338A (en) | Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction | |
| TW327598B (en) | N-acetonylbenzamide fungicides | |
| MY129094A (en) | Condensed polycyclic compounds | |
| YU89003A (en) | Prevention of addiction in pain management | |
| DK1049672T3 (en) | Azetidine carboxamide derivatives for the treatment of CNS disorders | |
| NZ334317A (en) | beta-lactam compounds as antibacterial agents effective against methicillin-resistant and coagulase-negative Staphylococci and process for preparing the same | |
| ES2103675A1 (en) | New substituted piperidines | |
| AP2001002314A0 (en) | Substituted benzolactam compounds. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |